Table 1 Comparison between patients with favorable and unfavorable outcomes regarding inflammatory biomarkers, stroke severity, and short-term outcome

Age (years), mean ± SD

63.3 ± 10.2

65.8 ± 10.2

T

0.9

0.3

 Male

12 (50%)

14 (38.9%)

χ²

0.724

0.395

 Female

12 (50%)

22 (61.1%)

 Yes

3 (12.5%)

5 (13.9%)

Fisher

0.02

0.877

 No

21 (87.5%)

31 (86.1%)

 Yes

20 (83.3%)

31 (86.1%)

Fisher

0.087

0.768

 No

4 (16.7%)

5 (13.9%)

 Yes

13 (54.2%)

21 (58.3%)

χ²

0.102

0.750

 No

11 (45.8%)

15 (41.7%)

 Yes

1 (4.2%)

4 (11.1%)

Fisher

0.909

0.340

 No

23 (95.8%)

32 (85.9%)

 Yes

6 (25%)

10 (27.8%)

χ²

0.057

0.812

 No

18 (75%)

26 (27.8%)

 Yes

9 (37.5%)

11 (30.6%)

χ²

0.313

0.576

 No

15 (62.5%)

25 (69.4%)

 Yes

3 (12.5%)

12 (33.3%)

χ²

3.33

0.068

 No

21 (87.5%)

24 (66.7%)

 Yes

7 (29.2%)

11 (30.6%)

χ²

0.013

0.908

 No

17 (70.8%)

25 (69.4%)

 Mild (>13)

14 (58.3%)

1 (2.8%)

χ²

23.7

15.3

Fisher

<0.001**

 Moderate (9–13)

10 (41.7%)

32 (88.9%)

<0.001**

 Severe (3–8)

0 (0.0%)

3 (8.3%)

0.2

NIHSS, median (range)

6 (5–16)

15 (8–21)

MW

5.9

<0.001**

White blood cell count (× 10³/μL), median (IQ range)

9.9 (6.4–11.1)

10.8 (7.5–13.1)

MW

3.6

0.04*

Neutrophil/lymphocyte ratio, median (IQ range)

2.5 (1.8–4.1)

5.2 (2.9–7.7)

MW

3.6

0.04*

C-reactive protein (mg/L), median (IQ range)

16.7 (5.2–46.7)

35.0 (19.2–83.0)

MW

2.2

0.02*

Erythrocyte sedimentation rate (mm), median (IQ range)

30.0 (20.0–55.8)

37.5 (23.5–57.5)

MW

1.0

0.3

 Yes

0 (0.0%)

10 (27.8%)

χ²

8.0

0.005*

 No

24 (100%)

26 (72.2%)

 Small

16 (66.7%)

4 (11.1%)

20

<0.001**

 Medium

7 (29.2%)

14 (38.9%)

0.6

0.4

 Large

1 (4.2%)

18 (50.0%)

14

<0.001**